Compare · DXCM vs STVN
DXCM vs STVN
Side-by-side comparison of DexCom Inc. (DXCM) and Stevanato Group S.p.A. (STVN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and STVN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.10B, about 6.3x STVN ($5.26B).
- DXCM has been more active in the news (6 items in the past 4 weeks vs 2 for STVN).
- DXCM has more recent analyst coverage (25 ratings vs 24 for STVN).
- Company
- DexCom Inc.
- Stevanato Group S.p.A.
- Price
- $86.05-1.93%
- $18.90-1.77%
- Market cap
- $33.10B
- $5.26B
- 1M return
- -2.13%
- -
- 1Y return
- +25.75%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2005
- 2021
- News (4w)
- 6
- 2
- Recent ratings
- 25
- 24
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Stevanato Group S.p.A.
Stevanato Group S.p.A. engages in the design, production, and distribution of products and systems to provide integrated solutions for pharma and healthcare. Its principal products are linked to containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machine. Stevanato Group S.p.A. was founded in 1949 and is based in Piombino Dese, Italy.
Latest DXCM
- Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
- Barclays initiated coverage on Dexcom with a new price target
- Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time
- Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
- EVP Chief People & Culture Off Stern Sadie sold $220,975 worth of shares (2,565 units at $86.15) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 123,478 units (SEC Form 4)
- Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
- EVP Chief Legal Compliance Off Brown Michael Jon sold $142,868 worth of shares (1,700 units at $84.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 99,885 units (SEC Form 4)
- Director Augustinos Nicholas sold $679,769 worth of shares (8,089 units at $84.04) as part of a pre-agreed trading plan (SEC Form 4)
- DexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Dexcom Promotes Jereme Sylvain to Chief Operating Officer
Latest STVN
- Deutsche Bank initiated coverage on Stevanato Group S.p.A.
- Officer Stocchi Mauro sold $293,454 worth of Ordinary Shares (13,649 units at $21.50), decreasing direct ownership by 3% to 400,000 units (SEC Form 4)
- UBS initiated coverage on Stevanato Group S.p.A.
- Stevanato Group to Participate in Two Upcoming Investor Conferences
- SEC Form SCHEDULE 13G filed by Stevanato Group S.p.A.
- Director Magistretti Elisabetta sold $41,084 worth of Ordinary Shares (2,045 units at $20.09), decreasing direct ownership by 41% to 2,930 units (SEC Form 4) to cover taxes
- Chief Financial Officer Dal Lago Marco sold $84,559 worth of Ordinary Shares (4,209 units at $20.09), decreasing direct ownership by 5% to 81,144 units (SEC Form 4) to cover withholding tax
- Director Santel Luciano sold $40,642 worth of Ordinary Shares (2,023 units at $20.09), decreasing direct ownership by 30% to 4,739 units (SEC Form 4) (withholding tax)
- SEC Form 6-K filed by Stevanato Group S.p.A.
- SEC Form 6-K filed by Stevanato Group S.p.A.